13F Holdings
中文EN

ELTX Elicio Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1601485 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY22.1%
TTM EPS YoY41.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-315.3%
ROA-105.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets52.4%
Debt / equity0.51x
Current ratio3.43x
Interest coverage-24.46x

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$2.30M$28.31M
Cost of revenue———$0$433,000
Gross profit———$2.30M$27.88M
R&D expense$24.90M$33.66M$23.85M$18.10M$48.70M
SG&A expense$12.81M$11.33M$11.90M$5.63M$18.49M
Operating income-$37.71M-$44.99M-$35.74M-$23.73M-$39.31M
Interest expense$1.13M$455,000$1.06M$3.60M—
Pretax income-$39.57M-$51.90M—-$38.80M-$54.57M
Income tax$0$0$0$0$0
Net income-$39.57M-$51.90M-$35.20M-$28.21M-$54.57M
EBITDA-$37.51M-$44.66M-$35.36M-$23.34M-$39.22M
EPS (basic)-2.58-4.25-6.96-89.27-1.93
EPS (diluted)-2.58-4.25-6.96-89.27-1.93
Weighted avg. shares (diluted)15.31M12.20M5.06M315,99828.24M
Banking
Net interest income———$805,000-$1.85M
Balance sheet
Cash & equivalents$18.56M$19.49M$14.30M$8.41M$10.04M
Receivables———$0—
Current assets$19.31M$20.69M$16.35M$10.72M$91.25M
PP&E, net$295,000$483,000$717,000$1.15M$451,000
Total assets$25.86M$28.18M$27.15M$22.66M$96.51M
Current liabilities$8.11M$11.52M$9.76M$6.87M$11.30M
Short-term debt$0————
Long-term debt$9.41M$20.03M——$0
Total debt$9.41M$20.03M——$0
Total liabilities$24.23M$39.49M$15.77M$13.75M$15.01M
Shareholders' equity$1.64M-$11.31M$11.37M-$102.14M-$74.54M
Net debt-$9.16M$542,000——-$10.04M
Shares outstanding17.80M11.03M9.60M320,28129.96M
Cash flow statement
Operating cash flow-$36.95M-$37.07M-$32.69M-$22.18M-$52.64M
Capital expenditure$16,000$87,000$66,000$654,000$382,000
Free cash flow-$36.97M-$37.16M-$32.76M-$22.83M-$53.02M
Investing cash flow-$16,000-$84,000-$32,000-$654,000-$382,000
Financing cash flow$36.70M$42.32M$38.61M$21.20M$107.17M
Depreciation & amortization$204,000$321,000$382,000$390,000$91,000
Stock-based compensation$2.70M$1.45M$1.18M$579,000$12.04M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.